BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2651576)

  • 1. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Redmond C; Wickerham DL; Bowman D; Schipper H; Wolmark N; Sass R; Fisher ER; Jochimsen P; Legault-Poisson S
    J Clin Oncol; 1989 May; 7(5):572-82. PubMed ID: 2651576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
    Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
    J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.
    Fisher B; Brown A; Wolmark N; Redmond C; Wickerham DL; Wittliff J; Dimitrov N; Legault-Poisson S; Schipper H; Prager D
    Ann Intern Med; 1987 May; 106(5):649-54. PubMed ID: 3551710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
    Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
    J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
    J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Redmond C; Fisher ER; Wolmark N
    NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
    Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
    Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10.
    Fisher B; Brown A; Wolmark N; Fisher ER; Redmond C; Wickerham DL; Margolese R; Dimitrov N; Pilch Y; Glass A
    Cancer; 1990 Jul; 66(2):220-7. PubMed ID: 2196108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.
    Fisher B; Fisher ER; Redmond C
    J Clin Oncol; 1986 Jun; 4(6):929-41. PubMed ID: 3519883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
    Fisher B; Anderson S; Tan-Chiu E; Wolmark N; Wickerham DL; Fisher ER; Dimitrov NV; Atkins JN; Abramson N; Merajver S; Romond EH; Kardinal CG; Shibata HR; Margolese RG; Farrar WB
    J Clin Oncol; 2001 Feb; 19(4):931-42. PubMed ID: 11181655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
    J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
    Levine MN; Gent M; Hryniuk WM; Bramwell V; Abu-Zahra H; DePauw S; Arnold A; Findlay B; Levin L; Skillings J
    J Clin Oncol; 1990 Jul; 8(7):1217-25. PubMed ID: 2193119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.